ISTO Technologies to Present at 2014 Stem Cell Meeting on the Mesa

ST. LOUIS, Sept. 30, 2014 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held regenerative medicine company, announced today announced that Mitchell Seyedin, Ph.D., the Company's Executive Chairman, will present at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa, as follows:

ISTO's presentation will also be published on the Alliance for Regenerative Medicine website shortly after the event.

Organized by the Alliance for Regenerative Medicine (ARM), the California Institute for Regenerative Medicine (CIRM) and the Sanford Consortium for Regenerative Medicine, the 2014 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior executives and top decision makers in the regenerative medicine industry with the scientific community to advance cutting-edge research into cures. The Partnering Forum is the first and only partnering meeting of its kind dedicated solely to facilitating connections for the regenerative medicine and advanced therapies industry.

The meeting also features a nationally recognized Scientific Symposium, showcasing leading academic research in the field of regenerative medicine. Combined, these meetings attract nearly 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

Complimentary attendance at this event is available for credentialed investors and members of the media only.  Investors and media wishing to attend should contact Laura Parsons at [email protected].

About ISTO Technologies, Inc. 

ISTO is a privately-held orthobiologics company dedicated to improving patient quality of life through the development of proprietary products for spinal therapies and sport medicine applications. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. The Company's proprietary cell-based orthobiologic platform harnesses the regenerative capacity of juvenile cartilage cells to create products designed to repair and restore function to damaged cartilage tissue. In addition to cell-based cartilage products in clinical development, ISTO manufactures and markets InQu^®, a bone graft extender and substitute for spinal fusion applications that has been used in over 30,000 surgeries at U.S. hospitals to date.  For additional information on ISTO, please visit our website at www.istotech.com.

SOURCE ISTO Technologies, Inc.